Stigma of mental health decreasing, but more resources needed
Booth stopped by WMBD This Morning to share thoughts, outlooks and discoveries during Mental Health Awareness month.
He said some recent improvements in mental health treatments include that since Covid, 'the 'stigma' has definitely gotten better. We are finding more spaces to be comfortable to talk about our mental health, without that 'stigma' attached, but there's still a lot more work to do.'
Some of that work includes, he continued, 'there's a lot of individuals that are suffering in silence, there's a lot of education that needs to be done, to understand what mental health issues feel like, and to also be able to recognize when you have a loved one or a friend that may be struggling with mental health and how to support them.'
The other side of the coin according to Booth, is that while resources have increased, the shrinking of the 'stigma' means more people are coming forward in need of services, 'and we're also seeing mental health concerns in youth younger and younger' he said.
Booth recommends that 'just like we go get physical checkups from our primary care provider, it's important for us to do our own mental health checkups.'
He also encourages self-mental Health checkups: ' That's just asking yourself, 'How am I feeling today? How am I doing? Do I feel feelings of worry or stress or depression? 'and then ask yourself what's causing those feelings.'
He also advises to 'make sure we're getting the basic needs like food, and sleep and exercise, and water, those basic things that help our physical health, but also help our mental health.'
Another important point to Booth is 'making sure you have at least one individual in your life that you can share with, that you can talk with, that can give you good advice.'
Booth recommends the 'Mental Health First-Aid' course available through Trillium Place.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Enanta Pharmaceuticals to Participate in the H.C. Wainwright
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. 'HCW@Home' series. A live webcast of the event will be accessible by visiting the 'Events and Presentations' section on the 'Investors' page of Enanta's website at or by registering here. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing Hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information.
Business Wire
2 hours ago
- Business Wire
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis. Enrollment is planned to begin later this year and will include patients with and without atrial fibrillation (AFib). There is a critical need for safe, effective anticoagulants for use in ESKD patients. Tecarfarin's orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. Share Patients with severe kidney disease are already at high risk for thrombotic cardiovascular events such as myocardial infarction and stroke, along with a much greater risk of AFib and venous thromboembolism compared to subjects with normal kidney function. When ESKD patients require dialysis, their transition period comes with even greater risk of myocardial infarction, stroke, and a substantial increase in mortality. 'There is a critical need for safe, effective anticoagulants for use in ESKD patients,' said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. 'Tecarfarin's orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. This study will be an important step forward for the continued development of tecarfarin in ESKD and in other areas with real opportunities to improve patient outcomes with a potentially better vitamin K antagonist.' Currently, there is limited evidence supporting the use of anticoagulant therapy in dialysis patients. Dialysis patients are often excluded from clinical trials due to their high underlying risk profile, and studies of direct oral anticoagulants (DOACs) in this patient population have not provided clear answers. Furthermore, a recent Phase 2 trial of chronic hemodialysis patients sponsored by a global company showed no benefit from the new class of Factor XI inhibitors in maintaining vascular access graft patency. To date, no prospective studies have examined the benefit of oral anticoagulation in preventing thrombotic events at the time of dialysis initiation. 'Initiating dialysis carries substantial excess risk of cardiovascular events and mortality, and to date, this risk has not been sufficiently addressed. Tecarfarin, a next-generation Vitamin K antagonist with a unique metabolism pathway that is not significantly affected by kidney impairment, has potential promise in this area of unmet need,' said Wolfgang Winkelmayer, Professor of Medicine and Chief of Nephrology at Baylor College of Medicine in Houston, Texas. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to address limitations of current anticoagulation therapy specifically. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of managing Vitamin K antagonists and where DOACs remain inadequate or unproven. Tecarfarin received Orphan Drug Designation (ODD) and fast-track status for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation (ESKD+AFib). The company also received ODD for the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs). The company has submitted an Orphan Drug Designation Request to the US FDA for patients with chronic kidney disease who have an implanted mechanical heart valve (and consequently require lifelong anticoagulation with a VKA) who also have genetic predisposition to impaired CYP2C9 metabolism, and resulting associated challenges with achieving reliable degrees of anticoagulation with the long-term use of warfarin. Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding initiation of clinical trial for tecarfarin in patients with ESKD transitioning to dialysis; initiation of registration trial in patients with ESKD and AFib, developing transformative therapeutics to specifically address limitations of current anticoagulation therapy; addressing a critical current treatment gap in patients with ESKD; enrollment in the planned clinical trial beginning later this year; the planned study being an important step forward for the continued development of tecarfarin in ESKD; improving patient outcomes with a potentially better vitamin K antagonist; tecarfarin offering potential promise in patients initiating dialysis; addressing the unmet needs in anticoagulation therapy; and Cadrenal's ability to pursue business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to specifically address limitations of current anticoagulation therapy; the ability to address a critical current treatment gap in patients with ESKD; the ability to advance an innovative solution to address the unmet needs in anticoagulation therapy; the ability to initiate and successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Newsweek
3 hours ago
- Newsweek
Six More States Ban Junk Food From SNAP Benefits
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Six more states have banned junk food purchases from being bought with Supplemental Nutrition Assistance Program (SNAP) benefits, the U.S. Department of Agriculture (USDA) has announced. West Virginia, Florida, Colorado, Louisiana, Oklahoma, and Texas have all had new waivers approved that allow each state to modify what can and can't be bought using food benefits. Across all of these states, the change will impact approximately 8.5 million people. It brings the total number of states banning junk purchases to 12, following similar waiver approvals earlier this year for Arkansas, Idaho, Indiana, Iowa, Nebraska and Utah. Why It Matters SNAP benefits, also known as "food stamps," are paid to low- and no-income households across the U.S. that would otherwise struggle to afford groceries. Across the country, more than 40 million people receive the allowance. A customer shops for produce at an H-E-B grocery store on February 12, 2025, in Austin, Texas. A customer shops for produce at an H-E-B grocery store on February 12, 2025, in Austin, Texas. Brandon Bell/GETTY What To Know A waiver grants flexibility by modifying specific USDA program rules, enabling states to administer the SNAP program in different ways. Various states currently have SNAP waivers in place, and they were widely implemented during the COVID-19 pandemic to help Americans get better access to food benefits. The new waivers, while different for each state, mean that starting in 2026 certain types of foods can no longer be bought using electronic benefit transfer cards, which are loaded every month with payments to spend in participating grocery providers across the country. Junk food generally refers to foods that have lots of calories, particularly those high in macronutrients such as sugar and fat, but little nutritional value. In Texas, the ban will cover soda, energy drinks, candy, and prepared desserts, while in Louisiana, soft drinks, energy drinks, and candy will be banned. Some of the waivers are less restrictive: in Colorado and West Virginia, only soft drinks will no longer be eligible for purchase. The push to tighten rules around unhealthy purchases has been led by Republican states, with Colorado being the only Democratic state to join the throng. Proponents of limiting SNAP purchases have argued removing unhealthy foods from the program will improve health outcomes, while others have argued that it controls how America's poorest eat and fails to address wider problems regarding access to affordable, healthy food. What People Are Saying Health and Human Services Secretary Robert F. Kennedy: "For years, SNAP has used taxpayer dollars to fund soda and candy—products that fuel America's diabetes and chronic disease epidemics. "These waivers help put real food back at the center of the program and empower states to lead the charge in protecting public health. I thank the governors who have stepped up to request waivers, and I encourage others to follow their lead. This is how we Make America Healthy Again." Texas Governor Greg Abbott: "To ensure the health and well-being of Texans, we must promote better, healthier food habits. Earlier this year, I requested a waiver from the USDA to ensure SNAP benefits cannot be used to purchase junk food. "I applaud [Agriculture] Secretary [Brooke L.] Rollins and the Trump Administration for their approval of this waiver to support and promote healthy eating habits. The state of Texas will continue to consider innovative ways for Texans to lead healthy and productive lives." Kavelle Christie, a health policy and advocacy expert and director at the Center for Regulatory Policy and Health Innovation, previously told Newsweek: "The issue isn't about individuals misusing their benefits, but their limited choices. In many rural areas and food deserts, convenience stores and fast-food chains are often the only available options. "For many families, fresh produce and healthy meals are luxuries that are unattainable, not because they do not want these foods, but because they are unavailable or too expensive." A food desert refers to an area, usually a low-income community, where residents have limited access to affordable and nutritious food, particularly fresh fruits and vegetables. What Happens Next Each of the waivers will go into effect in 2026, meaning there will be no immediate changes for SNAP beneficiaries across the impacted states for now. Most come into effect early next year.
